

Amendments to the Specification

Please add the following new paragraph after the after the title:

--This is the U.S. National Stage of International Application No. PCT/GB2003/004296, filed October 3, 2003 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain patent application no. 0223193.4 filed, October 7, 2002, and Great Britain patent application no. 0306261.9 filed March 19, 2003.--

Please amend the paragraph beginning on page 15, line 10 as follows:

--In preferred method of the invention said peptide comprises an amino acid sequence selected from the group consisting of: GPEETD (SEQ ID NO: 1); DGPEETD (SEQ ID NO: 2); TTLSDG (SEQ ID NO: 3); AEEFGDE (amino acids 294-299 of SEQ ID NO: 8); or PRNYFG (SEQ ID NO: 4).--

Please amend the paragraph beginning on page 15, line 20 as follows:

--In a further preferred method of the invention said peptide consists of an amino acid sequence consisting of: GPEETD (SEQ ID NO: 1); DGPEETD (SEQ ID NO: 2); TTLSDG (SEQ ID NO: 3); AEEFGDE (amino acids 294-299 of SEQ ID NO: 8); or PRNYFG (SEQ ID NO: 4).--

Please amend the paragraph beginning on page 19, line 26 as follows:

--According to an aspect of the invention there is provided a peptide comprising an amino acid sequence selected from the group consisting of: GPEETD (SEQ ID NO: 1); DGPEETD (SEQ ID NO: 2); TTLSDG (SEQ ID NO: 3); AEEFGDE (amino acids 294-299 of SEQ ID NO: 8); or PRNYFG (SEQ ID NO: 4).--

Please amend the paragraph beginning on page 20, line 6 as follows:

--In a further preferred embodiment of the invention said peptide consists of an amino acid sequence consisting of: GPEETD (SEQ ID NO: 1); DGPEETD (SEQ ID NO: 2); TTLSDG

(SEQ ID NO: 3); AEEFGDE (amino acids 294-299 of SEQ ID NO: 8); or PRNYFG (SEQ ID NO: 4).--

Please amend the paragraphs beginning on page 21, line 24 as follows:

-- Figure 1a is the nucleic acid sequence of human iASPP (SEQ ID NO: 6); Figure 1b is the C.elegans nucleic acid sequence of iASPP (SEQ ID NO: 7);

Figure 2a is the amino acid sequence of human iASPP (SEQ ID NO: 8); Figure 2b is the C.elegans amino acid sequence of iASPP (SEQ ID NO: 9);

Figure 3 illustrates that FITC labelled peptide (3a)DGPEETD (SEQ ID NO: 2) and (3b) TTLSDG (SEQ ID NO: 3) can penetrate cells;

Figure 4 illustrates the stimulation of the Bax promoter by p53 after incubation with various peptides, in particular DGPEETD (SEQ ID NO: 2);

Figure 5 illustrates the stimulation of p53 transactivation in a human tumour cell line U2SO after UV damage of DNA in the presence of peptide DGPEETD (SEQ ID NO: 2);

Please amend the paragraph beginning on page 23, line 16 as follows:

--Saos-2, MCF-7, and U2OS cells were grown in DMEM supplemented with 10% FCS, 100 IU/ml penicillin-streptomycin and 2 mM glutamine. Anti-p53 antibodies DO-1 and DO-13 are monoclonal antibodies while CM-1 is a rabbit polyclonal antibody specific to p53. The V5 and 9E10 epitopes are recognised by the mouse monoclonal antibodies V5 and 9E10 respectively. The mouse monoclonal PC-10 is specific to the PCNA protein. CD20Leu is an FITC conjugated monoclonal antibody specific for the cell surface marker CD20 (Becton Dickinson). The mouse and rabbit antibodies to ASPP1 and ASPP2 were described previously¹. Mouse and rabbit antibody to iASPP (peptide RLQPALPPEAQSVPELEE; SEQ ID NO: 5) was produced as described by Harlow and Lane¹³. All expression plasmids used in this study were

WDN/SLR:dm 01/19/05 332385
PATENT

Exhibit Mail No. EV514612324US
Date of Deposit: January 19, 2005
Attorney Reference Number 5585-69856-01
Application Number Currently Unknown

driven by the CMV immediate early promoter. ASPP1, iASPP and Ce-iASPP are tagged with V5 epitope while Ce-p53 is tagged with 9E10 epitope.--

Please insert the Abstract, submitted herewith on a separate page, as page 46 at the end of the application.